Skip to main content
Top
Published in: Endocrine 1/2015

01-05-2015 | Endocrine Imaging

Graves’ dermopathy and acropachy

Authors: Takafumi Taguchi, Hideki Nakajima, Yoshio Terada

Published in: Endocrine | Issue 1/2015

Login to get access

Excerpt

A 57-year-old woman was referred to hospital with verrucous nodules on her shins. Approximately 30 years ago, she underwent near-total thyroidectomy for hyperthyroidism and goiter diagnosed as Graves’ disease. Postoperatively, she had normal thyroid function with levothyroxine for 30 years, but her pretibial nodules were enlarged. Physical examination showed huge verrucous nodules on her shins and dorsa of the foot (Fig. 1a) and exophthalmos. Foot X-ray showed lobular lesions on bilateral shins (Fig. 1b, arrowheads). Hand X-ray showed fluffy periosteal reaction of bones (Fig. 1c, arrowheads), soft tissue swelling (Fig. 1c, asterisks), and digital clubbing which are compatible with thyroid acropachy. Laboratory examinations showed thyroid-stimulating hormone receptor antibody levels of 380 IU/L (normal, <2.0 IU/L), thyroid-stimulating antibody values of 3,758 % (normal, ≤180 %), and thyroid-stimulating hormone blocking antibody values of 100 % (normal, ≤45.6 %). Histological examination of the nodules showed epidermal acanthosis and mucinous degeneration. She was diagnosed with pretibial myxedema associated with Graves’ disease. Localized or pretibial myxedema is an infrequent extrathyroidal manifestation of Graves’ disease (along with goiter, exophthalmus, thyroid acropachy, and high circulating levels of long-acting thyroid-stimulating hormone), with late onset, often occurring after thyroidectomy or radioisotope therapy [1]. It is generally considered that thyroid dermopathy and acropachy occur with Graves’ ophthalmopathy, and appear to be markers of severe ophthalmopathy [2]. Subcutaneous injections of steroids were initiated with modest improvement of myxedema after 8 months.
Literature
1.
go back to reference S. Verma, F. Rongioletti, M. Braun-Falco, T. Ruzicka, Preradial myxedema in a euthyroid male: a distinct rarity. Dermatol. Online J. 19(4), 9 (2013)PubMed S. Verma, F. Rongioletti, M. Braun-Falco, T. Ruzicka, Preradial myxedema in a euthyroid male: a distinct rarity. Dermatol. Online J. 19(4), 9 (2013)PubMed
2.
go back to reference V. Fatourechi, G.B. Bartley, G.Z. Eghbali-Fatourechi, C.C. Powell, D.D. Ahmed, J.A. Garrity, Graves’ dermopathy and acropachy are markers of severe Graves’ ophthalmopathy. Thyroid 13(12), 1141–1144 (2003)CrossRefPubMed V. Fatourechi, G.B. Bartley, G.Z. Eghbali-Fatourechi, C.C. Powell, D.D. Ahmed, J.A. Garrity, Graves’ dermopathy and acropachy are markers of severe Graves’ ophthalmopathy. Thyroid 13(12), 1141–1144 (2003)CrossRefPubMed
Metadata
Title
Graves’ dermopathy and acropachy
Authors
Takafumi Taguchi
Hideki Nakajima
Yoshio Terada
Publication date
01-05-2015
Publisher
Springer US
Published in
Endocrine / Issue 1/2015
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-014-0389-5

Other articles of this Issue 1/2015

Endocrine 1/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine